nach oben

Journal of Endocrinological Investigation

Erschienen in:

01.08.2014 | Original Article

Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome

verfasst von: Esra Nur Ademoglu, Suheyla Gorar, Ayse Carlıoglu, Havva Yazıcı, Fatma Dilek Dellal, Zehra Berberoglu, Derya Akdeniz, Sema Uysal, Feridun Karakurt

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Nesfatin-1 is a recently discovered neuropeptide derived from its precursor nucleobindin-2 (NUCB2) and has been implicated in the regulation of feeding and energy metabolism. It is located in the brain and also produced at the periphery and present in the plasma. However, its pathophysiological role in humans remains unknown. Polycystic ovary syndrome (PCOS) is commonly presented with obesity, insulin resistance, hyperandrogenemia and hirsutism.

Aim

To characterize serum nesfatin-1 levels in PCOS women and determine association of nesfatin-1 with metabolic parameters.

Materials and methods

It is a cross-sectional study of 55 PCOS and 28 healthy women matched in age, in a university hospital setting. Anthropometric, hormonal, metabolic parameters and nesfatin-1 blood levels were determined.

Results

Nesfatin-1 levels were significantly higher in PCOS group compared with the controls 371.43 ± 2.50 versus 275.55 ± 1.74 pg/mL. Multivariate logistic regression analysis that contains: nesfatin-1, body mass index and homeostasis model assessment index revealed significant correlation of nesfatin-1 with the existence of PCOS (p < 0.05).

Conclusions

Higher nesfatin-1 levels in PCOS women compared to control group may suggest a possibility that nesfatin-1 may play some role in the PCOS.

Kohno D, Nakata M, Maejima Y et al (2008) Nesfatin-1 neurons in paraventricular and supraoptic nuclei of the rat hypothalamus coexpress oxytocin and vasopressin and are activated by refeeding. Endocrinology 149:1295–1301PubMedCrossRef

Brailoiu GC, Dun SL, Brailoiu E et al (2007) Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology 148:5088–5094PubMedCrossRef

Oh IS, Shimizu H, Satoh T et al (2006) Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 443:709–712CrossRef

Gonzalez R, Tiwari A, Unniappan S (2009) Pancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Biochem Biophys Res Commun 381:643–664PubMedCrossRef

Yada T, Dezaki K, Sone H et al (2008) Ghrelin regulates insulin release and glycemia: physiological role and therapeutic potential. Curr Diabetes Rev 4:18–23PubMedCrossRef

Meier JJ, Gallwitz B, Schmidt WE et al (2002) Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives. Eur J Pharmacol 440:269–279PubMedCrossRef

Nakata M, Manaka K, Yamamoto S et al (2011) Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca2+ influx through L-type channels in mouse islet β-cells. Endocr J 58:305–313PubMedCrossRef

Stengel A, Goebel M, Yakubov I et al (2009) Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 150:232–238PubMedCentralPubMedCrossRef

Ehrman DA (2005) Polycystic ovary syndrome. N Engl Med 352:1223–1236CrossRef

10.

Kandaraki E, Chatzigeorgiou A, Livanas S et al (2011) Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab 96:E480–E484PubMedCrossRef

11.

Mukherjee S, Maitra A (2010) Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J Med Res 131:743–760PubMed

12.

Dewailly D, Gronier H, Poncelet E et al (2011) Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 26:3123–3129PubMedCrossRef

13.

Zhang Z, Li L, Yang M et al (2012) Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 120:91–95PubMedCrossRef

14.

Deniz R, Gurates B, Aydin S et al (2012) Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine 42:694–699PubMedCrossRef

15.

Tsuchiya T, Shimizu H, Yamada M et al (2010) Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin Endocrinol (Oxf) 73:484–490

16.

Li QC, Wang HY, Chen X et al (2010) Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul Pept 159:72–77PubMedCrossRef

17.

Foo KS, Brauner H, Ostenson CG et al (2010) Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J Endocrinol 204:255–263PubMedCrossRef

18.

Aslan M, Celik O, Celik N et al (2012) Cord blood nesfatin-1 and apelin-36 levels in gestational diabetes mellitus. Endocrine 41:424–429PubMedCrossRef

19.

Iguchi H, Urashima Y, Inagaki Y et al (2007) SOX6 suppresses cyclin D1 promoter activity by interacting with beta-catenin and histone deacetylase 1, and its down-regulation induces pancreatic beta-cell proliferation. J Biol Chem 282:19052–19061PubMedCrossRef

20.

Ramanjaneya M, Chen J, Brown JE et al (2010) Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 151:3169–3180PubMedCrossRef

21.

Saldanha JF, Carrero JJ, Lobo JC et al (2012) The newly identified anorexigenic adipokine nesfatin-1 in hemodialysis patients: are there associations with food intake, body composition and inflammation? Regul Pept 173:82–85PubMedCrossRef

22.

Shimizu H, Oh-I S, Hashimoto K et al (2009) Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology 150:662–671PubMedCrossRef

Titel: Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome
verfasst von: Esra Nur Ademoglu
Suheyla Gorar
Ayse Carlıoglu
Havva Yazıcı
Fatma Dilek Dellal
Zehra Berberoglu
Derya Akdeniz
Sema Uysal
Feridun Karakurt
Publikationsdatum: 01.08.2014
Verlag: Springer International Publishing
Erschienen in: Journal of Endocrinological Investigation / Ausgabe 8/2014
Elektronische ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-014-0089-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Aim

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

Is prophylactic anti-resorptive therapy required in thyroid cancer patients receiving TSH-suppressive treatment with thyroxine?

Leonardo da Vinci “Design of Lady with Graves’ disease” (1452–1519)

Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods

Low-grade inflammation in overweight and obese adults is affected by weight loss program

Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women

Effects of cocaine on the hypothalamic–pituitary–adrenal axis